AUS
NZ
UK
CA
USA
IND
Highlights:
- Vivos Therapeutics receives new AMA CPT codes for enhanced insurance reimbursement of OSA treatments.
- FDA clears Vivos CARE oral devices for effective treatment of sleep apnea in children and adults.
- Over 31,000 patients treated globally with Vivos' innovative noninvasive methods.
Vivos Therapeutics, Inc. (NASDAQ:VVOS) is making significant strides in the medical technology field with its groundbreaking approach to diagnosing and treating sleep disorders, particularly obstructive sleep apnea (OSA). The company has recently secured pivotal advancements, including streamlined insurance reimbursement and FDA clearance for its pediatric OSA device, solidifying its position as a leader in noninvasive sleep solutions.
As of October 8, 2024, Vivos announced that the American Medical Association (AMA) has granted new Current Procedural Terminology (CPT) codes specifically for its Vivos CARE oral medical devices. Set to take effect on January 1, 2025, these new codes are expected to simplify the insurance coverage and reimbursement process for Vivos' innovative devices. This development is particularly crucial for expanding access to treatment, allowing a broader patient base to benefit from the company’s FDA-cleared airway remodeling technology.
CEO Kirk Huntsman emphasized the significance of these new codes, noting that they will facilitate coverage by commercial medical insurance payers. “Our CARE oral medical devices are the only ones cleared by the US FDA for the treatment of moderate to severe OSA,” Huntsman stated. The addition of these medical codes aligns with Vivos' mission to make effective treatments more accessible to patients suffering from sleep-related breathing disorders.
The Vivos Method represents a novel approach to addressing mild to moderate OSA and snoring issues. It is clinically effective, nonsurgical, noninvasive, and cost-effective, distinguishing it from traditional treatment options. The company has successfully treated over 31,000 patients worldwide, collaborating with more than 1,650 trained dentists to implement its innovative solutions.
Vivos Therapeutics' commitment to improving patient outcomes has gained attention in the medical community. The Vivos CARE devices are designed to promote airway remodeling, effectively addressing the underlying causes of sleep apnea rather than merely managing its symptoms. This focus on treating root causes positions Vivos as a transformative player in the sleep health market.
In addition to its recent achievements, Vivos is also making headway in pediatric care. The recent FDA clearance for its pediatric OSA device underscores the company's dedication to addressing the needs of younger patients, who are increasingly being diagnosed with sleep-related disorders. This move not only expands Vivos' product portfolio but also highlights the urgency of addressing OSA across all age groups.
As the awareness of sleep apnea and its health implications continues to grow, Vivos Therapeutics is poised to benefit from an expanding market. The integration of new CPT codes for insurance reimbursement, along with FDA approvals, strengthens its operational foundation and provides a pathway for sustained growth.
In summary, Vivos Therapeutics, Inc. is at the forefront of a significant shift in how sleep disorders are diagnosed and treated. By focusing on noninvasive, cost-effective solutions, the company is not only improving patient access to necessary treatments but is also setting new standards in the medical technology landscape. With a growing patient base and innovative products, Vivos is well-positioned for future success in the fight against obstructive sleep apnea and related conditions.
